Octagon Capital Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Octagon Capital Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$163M	Sell	1,946,667 -470,000	-19%	-$27.2M	18.08%	1
2025 Q4	$99.6M	Hold	2,416,667	–	–	12.09%	2
2025 Q3	$95.1M	Buy	2,416,667 +75,000	+3%	+$1.92M	14.41%	2
2025 Q2	$43.6M	Hold	2,341,667	–	–	9.57%	1
2025 Q1	$42.5M	Buy	2,341,667 +231,500	+11%	+$5.1M	8.22%	3
2024 Q4	$46M	Buy	2,110,167 +363,500	+21%	+$9.35M	7.57%	3
2024 Q3	$47.8M	Hold	1,746,667	–	–	7.44%	4
2024 Q2	$45.2M	Buy	1,746,667 +366,000	+27%	+$8.8M	7.1%	2
2024 Q1	$41.4M	Buy	1,380,667 +826,667	+149%	+$18M	4.96%	3
2023 Q4	$5.76M	Buy	554,000 +74,000	+15%	+$817K	0.92%	23
2023 Q3	$6.56M	Buy	480,000 +445,625	+1,296%	+$5.61M	1.01%	22
2023 Q2	$417K	Buy	+34,375	New	+$391K	0.06%	39

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Octagon Capital Advisors's DNTH Position: Q1 2026 in Review

Octagon Capital Advisors reduced its Dianthus Therapeutics (DNTH) stake by 19% in Q1 2026, selling an estimated $27.2M and leaving 1,946,667 shares worth $163M. The position accounts for 18.08% of the portfolio, ranked #1.

Octagon Capital Advisors first reported a position in DNTH in Q2 2023 and has held it in 12 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Octagon Capital Advisors held 1,946,667 shares of Dianthus Therapeutics worth $163M as of Q1 2026.
Octagon Capital Advisors sold 470,000 Dianthus Therapeutics shares in Q1 2026, an estimated $27.2M.
Dianthus Therapeutics made up 18.08% of Octagon Capital Advisors's portfolio in Q1 2026, its #1 holding.
Octagon Capital Advisors first reported a position in Dianthus Therapeutics in Q2 2023 and has held it in 12 quarters since.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.